Takeda Pharmaceutical, a global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide, has joined the Massachusetts Institute of Technology Center for Biomedical Innovation’s New Drug Development Paradigms (NEWDIGS) initiative.
 
Takeda Pharmaceutical will collaborate on the Learning Ecosystems Accelerator for Patient-centered, Sustainable Innovation (LEAPS) project. LEAPS, a multi-stakeholder collaboration, advances the knowledge, practice, and sustainability of precision medicine through the coordinated innovation of next generation reimbursement and real-world evidence (RWE) production solutions. Within NEWDIGS’ safe haven environment, LEAPS collaborators design and pilot new, scalable RWE production platforms and payment models that improve the use of targeted drug therapy regimens.
 
“We warmly welcome Takeda as an important thought partner and collaborator in NEWDIGS. The culture and values of Takeda are well-aligned with our focus on biomedical system innovations that improve patient outcomes in economically sustainable ways,” said Gigi Hirsch, MD, Executive Director of NEWDIGS.